<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>来自 Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) 的公告现已发布。</p>
<p>Jacobio Pharmaceuticals 一直在根据现有授权稳步回购自家股票，累计回购 747,800 股库存股，总成本约为 3417 万港元。董事会认为当前股价低估了公司的核心肿瘤学管线和商业化潜力，并通过保留根据市场情况进行进一步回购的选项，表明了持续的信心。</p>
<p>公司的流动性得到了来自与阿斯利康的战略合作的 1 亿美元预付款和来自 Allist 的 855 万人民币的特许权使用费的支持，使其现金、资本保护存款和可用银行信贷总额达到约 21 亿元人民币。管理层估计，这笔现金流将持续至少四年，支持其肿瘤学产品组合的持续开发和全球扩张，从而支撑其长期战略和增强股东价值的承诺。</p>
<p>关于 (HK:1167) 股票的最新分析师评级为买入，目标价为 10.34 港元。要查看 Jacobio Pharmaceuticals Group Co., Ltd. 股票的完整分析师预测列表，请参见 HK:1167 股票预测页面。</p>
<p><strong>关于 Jacobio Pharmaceuticals Group Co., Ltd. 的更多信息</strong></p>
<p>Jacobio Pharmaceuticals Group 是一家注册于开曼群岛的生物技术公司，专注于开发创新的肿瘤学疗法。该集团专注于核心肿瘤药物管线，旨在实现商业化和全球业务扩展，定位于制药行业的癌症治疗领域。</p>
<p><strong>平均交易量：</strong> 3,166,367</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 45.3 亿港元</p>

加科思-B

<p>Jacobio Pharmaceuticals 已回购 747,800 股，耗资 3417 万港元，理由是其肿瘤学管线被低估。该公司通过来自阿斯利康的 1 亿美元付款和 855 万人民币的版税增强了流动性，总现金和信贷约为 21 亿人民币。这一财务实力支持持续的肿瘤学开发和全球扩张。分析师将该股票评级为买入，目标价为 10.34 港元</p>

<h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>An announcement from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) is now available.</p>
<div class="lb-trans"><p>来自 Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) 的公告现已发布。</p>
</div><p>Jacobio Pharmaceuticals has been steadily repurchasing its own shares under an existing mandate, accumulating 7,47,800 treasury shares at a total cost of about HK$34.17 million. The board argues that the current share price undervalues the company’s core oncology pipeline and commercialization potential, and signals continued confidence by reserving the option to conduct further buybacks depending on market conditions.</p>
<div class="lb-trans"><p>Jacobio Pharmaceuticals 一直在根据现有授权稳步回购自家股票，累计回购 747,800 股库存股，总成本约为 3417 万港元。董事会认为当前股价低估了公司的核心肿瘤学管线和商业化潜力，并通过保留根据市场情况进行进一步回购的选项，表明了持续的信心。</p>
</div><p>The company’s liquidity has been bolstered by a US$100 million upfront payment from its strategic collaboration with AstraZeneca and RMB8.55 million in royalties from Allist, bringing its cash, capital‑protected deposits and available bank credit to roughly RMB2.1 billion. Management estimates this cash runway will last at least four years, supporting ongoing development of its oncology portfolio and global expansion, which in turn underpins its long‑term strategy and commitment to enhancing shareholder value.</p>
<div class="lb-trans"><p>公司的流动性得到了来自与阿斯利康的战略合作的 1 亿美元预付款和来自 Allist 的 855 万人民币的特许权使用费的支持，使其现金、资本保护存款和可用银行信贷总额达到约 21 亿元人民币。管理层估计，这笔现金流将持续至少四年，支持其肿瘤学产品组合的持续开发和全球扩张，从而支撑其长期战略和增强股东价值的承诺。</p>
</div><p>The most recent analyst rating on (HK:1167) stock is a Buy with a HK$10.34 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.</p>
<div class="lb-trans"><p>关于 (HK:1167) 股票的最新分析师评级为买入，目标价为 10.34 港元。要查看 Jacobio Pharmaceuticals Group Co., Ltd. 股票的完整分析师预测列表，请参见 HK:1167 股票预测页面。</p>
</div><p><strong>More about Jacobio Pharmaceuticals Group Co., Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 Jacobio Pharmaceuticals Group Co., Ltd. 的更多信息</strong></p>
</div><p>Jacobio Pharmaceuticals Group is a Cayman Islands–incorporated biotechnology company focused on developing innovative oncology therapies. The group concentrates on core oncology drug pipelines with a view to commercialization and global business expansion, positioning itself within the cancer treatment segment of the pharmaceutical industry.</p>
<div class="lb-trans"><p>Jacobio Pharmaceuticals Group 是一家注册于开曼群岛的生物技术公司，专注于开发创新的肿瘤学疗法。该集团专注于核心肿瘤药物管线，旨在实现商业化和全球业务扩展，定位于制药行业的癌症治疗领域。</p>
</div><p><strong>Average Trading Volume:</strong> 3,166,367</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 3,166,367</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$4.53B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 45.3 亿港元</p>
</div>

Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances

随着肿瘤研发管线的推进，加科思-B 增加了股票回购和流动性